229 related articles for article (PubMed ID: 27680756)
21. Compatibility of fosfomycin with different commercial peritoneal dialysis solutions.
Kussmann M; Baumann A; Hauer S; Pichler P; Zeitlinger M; Wiesholzer M; Burgmann H; Poeppl W; Reznicek G
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2237-2242. PubMed ID: 28685187
[TBL] [Abstract][Full Text] [Related]
22. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Burgess DS; Hall RG
Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
[TBL] [Abstract][Full Text] [Related]
23. Antibiotic-induced release of endotoxin: in-vitro comparison of meropenem and other antibiotics.
Trautmann M; Zick R; Rukavina T; Cross AS; Marre R
J Antimicrob Chemother; 1998 Feb; 41(2):163-9. PubMed ID: 9533457
[TBL] [Abstract][Full Text] [Related]
24. Peritoneal fluid titer test for peritoneal dialysis-related peritonitis.
Strijack C; Harding GK; Ariano RE; Zelenitsky SA
Antimicrob Agents Chemother; 2004 May; 48(5):1719-26. PubMed ID: 15105126
[TBL] [Abstract][Full Text] [Related]
25. Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus.
Lemaire S; Van Bambeke F; Mingeot-Leclercq MP; Tulkens PM
J Antimicrob Chemother; 2005 Jun; 55(6):897-904. PubMed ID: 15860552
[TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids.
Tobudic S; Poeppl W; Kratzer C; Vychytil A; Burgmann H
Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1327-34. PubMed ID: 22009289
[TBL] [Abstract][Full Text] [Related]
27. Improved Outcome of Enteric Peritonitis in Peritoneal Dialysis Patients Aged 50 Years and Older with Temporary Discontinuation of Peritoneal Dialysis and Intravenous Meropenem.
Abrahams AC; Rüger W; Ter Wee PM; van Ittersum FJ; Boer WH
Perit Dial Int; 2017; 37(3):298-306. PubMed ID: 28096441
[TBL] [Abstract][Full Text] [Related]
28. Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.
Tang HJ; Chen CC; Zhang CC; Cheng KC; Chiang SR; Chiu YH; Ku YH; Ko WC; Chuang YC
Antimicrob Agents Chemother; 2012 Jun; 56(6):2916-22. PubMed ID: 22470122
[TBL] [Abstract][Full Text] [Related]
29. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Raveh D; Yinnon AM; Broide E; Rudensky B
Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
[TBL] [Abstract][Full Text] [Related]
30. Human Bile Reduces Antimicrobial Activity of Selected Antibiotics against Enterococcus faecalis and Escherichia coli
Wulkersdorfer B; Jaros D; Eberl S; Poschner S; Jäger W; Cosentini E; Zeitlinger M; Schwameis R
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559254
[TBL] [Abstract][Full Text] [Related]
31. Bactericidal effect of combinations of antibiotic and antineoplastic agents against Staphylococcus aureus and Escherichia coli.
Nyhlén A; Ljungberg B; Nilsson-Ehle I; Odenholt I
Chemotherapy; 2002 May; 48(2):71-7. PubMed ID: 12011538
[TBL] [Abstract][Full Text] [Related]
32. Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
Hosgor-Limoncu M; Ermertcan S; Tasli H; Yurtman AN
West Indian Med J; 2008 Mar; 57(2):106-11. PubMed ID: 19565951
[TBL] [Abstract][Full Text] [Related]
33. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
[TBL] [Abstract][Full Text] [Related]
34. Three-year analysis of microbial aetiology and antimicrobial susceptibilities of PD peritonitis.
Leppänen H; Metsärinne KP; Nikoskelainen J; Tertti R
Scand J Infect Dis; 2006; 38(8):645-9. PubMed ID: 16857609
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.
Zhanel GG; Denisuik A; Vashisht S; Yachison C; Adam HJ; Hoban DJ
J Antimicrob Chemother; 2014 Sep; 69(9):2448-52. PubMed ID: 24827891
[TBL] [Abstract][Full Text] [Related]
36. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W
BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240
[TBL] [Abstract][Full Text] [Related]
37. Genotypic resistance determined by whole genome sequencing versus phenotypic resistance in 234 Escherichia coli isolates.
Vanstokstraeten R; Piérard D; Crombé F; De Geyter D; Wybo I; Muyldermans A; Seyler L; Caljon B; Janssen T; Demuyser T
Sci Rep; 2023 Jan; 13(1):449. PubMed ID: 36624272
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Erdem I; Kucukercan M; Ceran N
Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
[TBL] [Abstract][Full Text] [Related]
39. Impact of susceptibility profiles of Gram-negative bacteria before and after the introduction of ertapenem at a medical center in northern Taiwan from 2004 to 2010.
Lee CM; Lai CC; Wang YY; Lee MC; Hsueh PR
Diagn Microbiol Infect Dis; 2013 Jan; 75(1):94-100. PubMed ID: 23116904
[TBL] [Abstract][Full Text] [Related]
40. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
